A mouse model of the fragile gene FHIT:: From carcinogenesis to gene therapy and cancer prevention

被引:15
作者
Zanesi, N [1 ]
Pekarsky, Y [1 ]
Croce, CM [1 ]
机构
[1] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
关键词
mouse models; FHIT; fragile site; tumor spectrum; carcinogenesis; gene delivery;
D O I
10.1016/j.mrfmmm.2005.05.016
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 [微生物学]; 0836 [生物工程]; 090102 [作物遗传育种]; 100705 [微生物与生化药学];
摘要
Mouse models of tumor suppressors are increasingly useful to investigate biomedical aspects of cancer genetics. Some tumor suppressor genes are located at common fragile sites that are specific chromosomal regions highly susceptible to DNA lesions. The tumor suppressor gene FHIT, at the fragile site FRA3B, is the first fragile gene with a developed and characterized mouse knockout model. The human gene FHIT is frequently deleted in cancers and cancer cell lines of many epithelial tissues, and Fhit protein is absent or reduced in most cancers. The mouse Fhit ortholog is also located at a common fragile site, Fra14A2 on murine chromosome 14, and sustains homozygous deletions in murine cancer cell lines. The Fhit knockout mouse is, therefore, an adequate model to study human FHIT function. To establish an animal model and to explore the role of FHIT in tumorigenesis, we have developed a mouse strain carrying one or two inactivated Fhit alleles. Insights into Fhit mouse genetics that have emerged in the last 7 years, and are reviewed in the present article, allowed for development of new tools in carcinogenesis and gene delivery studies. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:103 / 109
页数:7
相关论文
共 42 条
[1]
EFFECT OF RADIATION AND CIGARETTE-SMOKING ON EXPRESSION OF FUDR-INDUCIBLE COMMON FRAGILE SITES IN HUMAN PERIPHERAL LYMPHOCYTES [J].
BAN, S ;
COLOGNE, JB ;
NERIISHI, K .
MUTATION RESEARCH-ENVIRONMENTAL MUTAGENESIS AND RELATED SUBJECTS, 1995, 334 (02) :197-203
[2]
Bednarek AK, 2000, CANCER RES, V60, P2140
[3]
SPECIFIC INDUCTION OF BLADDER CANCER IN MICE BY BUTYL-(4-HYDROXYBUTYL)-NITROSAMINE AND EFFECTS OF HORMONAL MODIFICATIONS ON SEX DIFFERENCE IN RESPONSE [J].
BERTRAM, JS ;
CRAIG, AW .
EUROPEAN JOURNAL OF CANCER, 1972, 8 (06) :587-&
[4]
Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27 (Publication with Expression of Concern. See vol. 114, 2017) [J].
Cesari, R ;
Martin, ES ;
Calin, GA ;
Pentimalli, F ;
Bichi, R ;
McAdams, H ;
Trapasso, F ;
Drusco, A ;
Shimizu, M ;
Mascillo, V ;
d'Andrilli, G ;
Scambia, G ;
Picchio, MC ;
Alder, H ;
Godwin, AK ;
Croce, CM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (10) :5956-5961
[5]
INCREASED CHROMOSOME FRAGILITY AS A CONSEQUENCE OF BLOOD FOLATE LEVELS, SMOKING STATUS, AND COFFEE CONSUMPTION [J].
CHEN, ATL ;
REIDY, JA ;
ANNEST, JL ;
WELTY, TK ;
ZHOU, HG .
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 1989, 13 (04) :319-324
[6]
FHIT gene therapy prevents tumor development in Fhit-deficient mice [J].
Dumon, KR ;
Ishii, H ;
Fong, LYY ;
Zanesi, N ;
Fidanza, V ;
Mancini, R ;
Vecchione, A ;
Baffa, R ;
Trapasso, F ;
During, MJ ;
Huebner, K ;
Croce, CM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (06) :3346-3351
[7]
Entius MM, 2000, CLIN CANCER RES, V6, P1784
[8]
The murine gene p27Kip1 is haplo-insufficient for tumour suppression [J].
Fero, ML ;
Randel, E ;
Gurley, KE ;
Roberts, JM ;
Kemp, CJ .
NATURE, 1998, 396 (6707) :177-180
[9]
Muir-Torre-like syndrome in Fhit-deficient mice [J].
Fong, LYY ;
Fidanza, V ;
Zanesi, N ;
Lock, LF ;
Siracusa, LD ;
Mancini, R ;
Siprashvili, Z ;
Ottey, M ;
Martin, SE ;
Druck, T ;
McCue, PA ;
Croce, CM ;
Huebner, K .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (09) :4742-4747
[10]
Development of spontaneous tumours and intestinal lesions in Fhit gene knockout mice [J].
Fujishita, T ;
Doi, Y ;
Sonoshita, M ;
Hiai, H ;
Oshima, M ;
Huebner, K ;
Croce, CM ;
Taketo, MM .
BRITISH JOURNAL OF CANCER, 2004, 91 (08) :1571-1574